NASDAQ:TENX

Tenax Therapeutics Q4 2024 Earnings Results & Report

Tenax Therapeutics logo
$1.42 -0.06 (-4.05%)
Closing price 04:00 PM Eastern
Extended Trading
$1.46 +0.04 (+2.46%)
As of 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tenax Therapeutics beat analyst earnings expectations in its Q4 2024 results, released March 25, 2025. The company reported EPS of -$0.18 versus the -$0.52 consensus estimate.

Earnings Announcement Details

Quarter
Q4 2024
Report Date
Time
Before Market Opens
Conference Call
8:00 AM ET

Tenax Therapeutics EPS Results

Actual EPS
-$0.18
Consensus EPS
-$0.52
Beat/Miss
Beat by +$0.34
One Year Ago EPS
N/A
EPS Beat Rate
8 of last 8 quarters

Tenax Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Tenax Therapeutics Q4 2024 Earnings FAQ

Tenax Therapeutics (NASDAQ:TENX) reported earnings of -$0.18 per share for Q4 2024, beating the consensus estimate of -$0.52. The report was announced on Tuesday, March 25, 2025.

Tenax Therapeutics Earnings Headlines

Top Trader Reveals Stunning Black Friday Deal
Others paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.tc pixel
See More Tenax Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tenax Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tenax Therapeutics and other key companies, straight to your email.

About Tenax Therapeutics

Tenax Therapeutics (NASDAQ:TENX) is a clinical-stage biopharmaceutical company focused on developing treatments for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), a condition involving elevated pressure in the lung’s blood vessels and impaired heart function.

The company’s lead program is levosimendan, a drug being developed in different formulations for PH-HFpEF. Tenax has described its development program as including oral, intravenous and subcutaneous formulations. Levosimendan is approved for certain heart-failure uses in some countries, but Tenax is studying it for a different indication.

Tenax Therapeutics is based in Morrisville, North Carolina, and its work centers on clinical development rather than marketing an established commercial product.

View Tenax Therapeutics Profile